News On ProSomnus Inc. (OSA) Now Under OSAP
News On ProSomnus Inc. (OSA) Now Under OSAP
Dow JonesApr 18 17:08 ET
ProSomnus, Inc. Common Stock (NASDAQ:OSA) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 30 09:34 ET
Prosomnus, Inc.: Navigating Market Volatility and Liquidity Risks Post-Merger
TipRanksMar 28 02:03 ET
Q4 2023 Prosomnus Inc Earnings Call
Yahoo FinanceMar 27 09:34 ET
Analysts Offer Insights on Healthcare Companies: ProSomnus (OSA), Merck & Company (MRK) and Phreesia (PHR)
TipRanksMar 27 08:30 ET
ProSomnus Q4 Sales $7.84M Beat $7.37M Estimate
ProSomnus (NASDAQ:OSA) reported quarterly sales of $7.84 million which beat the analyst consensus estimate of $7.37 million by 6.35 percent. This is a 35.32 percent increase over sales of $5.79 millio
BenzingaMar 27 08:00 ET
Earnings Call Summary | ProSomnus(OSA.US) Q4 2023 Earnings Conference
The following is a summary of the ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript:Financial Performance:ProSomnus reported a record revenue for Q4 2023 of $7.8 million and a full-year 2023 reve
moomoo AIMar 27 00:45 ET · Conference Call
ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
Earnings Call TranscriptsMar 27 00:15 ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersApollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. Cara Therapeutics (NASDAQ:CARA) share
BenzingaMar 26 17:32 ET
ProSomnus Reports Q4 Results
Seeking AlphaMar 26 16:47 ET
ProSomnus 4Q Rev $7.84M >OSA
ProSomnus 4Q Rev $7.84M >OSA
Dow JonesMar 26 16:08 ET
Press Release: ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy(TM) f
Dow JonesMar 26 16:05 ET
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. • AIM ImmunoTech (AMEX:AIM) is estimated to report
BenzingaMar 26 04:47 ET
Craig-Hallum Reaffirms Their Hold Rating on ProSomnus (OSA)
TipRanksMar 18 08:36 ET
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, announced today it has postponed the release of
GlobeNewswireMar 15 20:01 ET
Top 4 Health Care Stocks That Are Preparing To Pump This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
BenzingaFeb 23 07:50 ET
Investors Give ProSomnus, Inc. (NASDAQ:OSA) Shares A 30% Hiding
Unfortunately for some shareholders, the ProSomnus, Inc. (NASDAQ:OSA) share price has dived 30% in the last thirty days, prolonging recent pain.
Simply Wall StFeb 23 07:43 ET
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, announced results of its pilot study for the
GlobeNewswireFeb 22 08:30 ET
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024
PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it will rep
GlobeNewswireFeb 20 16:05 ET
ProSomnus Faces Multiple Nasdaq Listing Compliance Issues
TipRanksFeb 16 17:24 ET
No Data
No Data